Axonics, Inc.(AXNX) Stock Research - Grey Stern Research

Axonics, Inc. (AXNX) Stock Analysis

$70.98 (0.00%)

AXNX Financial Performance


Use the table below to view Axonics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $70.98 -
52 Week Low $70.98 -
52 Week High $70.98 -
Market Cap $3.6 Billion 5/17
Gross Margin 77% 2/17
Profit Margin 0% 8/17
EBITDA margin -5% 11/17
Q3 - 2024 Revenue $116.2 Million 10/17
Q3 - 2024 Earnings -$21,000 8/17
Q3 - 2024 Free Cash Flow -$2.4 10/17
Trailing 4 Quarters Revenue $431.9 Million 10/17
Trailing 4 Quarters Earnings -$5.7 Million 7/17
Quarterly Earnings Growth -101% 16/17
Annual Earnings Growth 69% 2/17
Quarterly Revenue Growth 25% 4/17
Annual Revenue Growth 168% 1/17
Cash On Hand $239.5 Million 5/17
Short Term Debt $2.6 Million 11/17
Long Term Debt $29.9 Million 15/17

Axonics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Axonics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 7/17
PS 8.40 3/17
PB 5.46 4/17
PC 15.15 9/17
Liabilities to Equity 0.17 16/17
ROA -0.01 8/17
ROE -0.01 8/17
Current Ratio 7.06 2/17
Quick Ratio 3.15 1/17
Long Term Debt to Equity 0.04 16/17
Debt to Equity 0.05 16/17
Burn Rate 128.07 1/17
Cash to Cap 0.07 9/17
CCR 114.05 1/17
EV to EBITDA -545.75 16/17
EV to Revenue 7.92 3/17

Company Details

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

CEO: Mr. Raymond Cohen

Website: https://www.axonics.com

Address: 26 Technology Dr Irvine, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Devices

Axonics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Axonics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Medtronic plc MDT $107.9 Billion
Glaukos Corporation GKOS $5.5 Billion
LivaNova PLC LIVN $2.0 Billion
Bruker Corporation BRKR $5.9 Billion
NuVasive, Inc. NUVA $2.1 Billion
Integra LifeSciences Holdings Corporation IART $1.3 Billion
iRhythm Technologies, Inc. IRTC $3.4 Billion
Integer Holdings Corporation ITGR $4.3 Billion
CONMED Corporation CNMD $1.6 Billion
Heska Corporation HSKA $1.3 Billion
Orthofix Medical Inc. OFIX $553.7 Million
OrthoPediatrics Corp. KIDS $534.9 Million
SI-BONE, Inc. SIBN $611.7 Million
Pulmonx Corporation LUNG $209.3 Million
Nano-X Imaging Ltd. NNOX $334.8 Million
NeuroPace, Inc. NPCE $362.9 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
AXNX Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 116.2 Million -$21,000
Q2 2024 $ 114.6 Million $6.9 Million
Q1 2024 $ 91.4 Million -$19.1 Million
Q4 2023 $ 109.7 Million $6.6 Million
Q3 2023 $ 93.1 Million $3.9 Million
Q2 2023 $ 22.7 Million -$7.3 Million
Q1 2023 $ 70.7 Million -$9.2 Million
Q4 2022 $ 85.9 Million $665,000

View All

AXNX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $239.5 Million $774.2 Million $32.5 Million $664.5 Million
Q2 2024 $168.6 Million $747.3 Million $32.5 Million $643.3 Million
Q1 2024 $232.6 Million $715.6 Million $31.6 Million $627.1 Million
Q4 2023 $104.8 Million $719.9 Million $27.6 Million $637.6 Million
Q3 2023 $147.3 Million $660.7 Million $2.8 Million $610.6 Million
Q2 2023 $3.0 Million $649.0 Million $3.0 Million -$18.3 Million
Q1 2023 $240.1 Million $665.7 Million $8.7 Million $576.6 Million
Q4 2022 $238.8 Million $659.4 Million $9.1 Million $570.1 Million

View All

AXNX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$2.4 Million -$3.3 Million $92.9 Million
Q2 2024 $15.7 Million -$1.2 Million -$64.0 Million
Q1 2024 -$12.3 Million -$3.1 Million $130.9 Million
Q4 2023 $4.3 Million -$1.3 Million -$42.5 Million
Q3 2023 $11.2 Million -$1.2 Million $2.0 Million
Q2 2023 -$19.5 Million -$256,000 -$94.8 Million
Q1 2023 -$1.6 Million -$794,000 $1.3 Million
Q4 2022 $9.0 Million -$335,000 -$2.5 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions